waltham

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory…

1 week ago

Cambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts

EAST RUTHERFORD, N.J., Aug. 25, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced…

2 weeks ago

FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of…

1 month ago

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

July 08, 2025 21:36 ET  | Source: Cogent Biosciences, Inc. WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE)…

2 months ago